Last updated: February 27, 2026
What Is the Scope of Patent SI2049506?
Patent SI2049506 covers a pharmaceutical invention, specifically a novel compound or formulation. It claims a unique molecular structure with specific pharmacological activity, intended to treat a defined condition or disease. The patent’s scope includes:
- The chemical composition with structural formulas specified in the claims.
- Methods of preparing the compound.
- Uses of the compound in treating particular medical conditions.
- Alternative formulations and delivery systems.
The patent is filed by [Applicant/Assignee], with priority data from [filing date], and was granted in Slovenia on [grant date]. It is valid until [expiration date], typically 20 years from filing, with potential extensions.
What Are the Key Claims?
The claims define the scope and enforceability of the patent. SI2049506’s core claims encompass:
- Chemical Structure Claims: Covering the specific molecular entity, including variations with certain substitutions that retain activity.
- Method of Synthesis: Details of chemical processes to produce the compound, including reaction steps and catalysts.
- Use Claims: Methods of using the compound in treatment, targeting specific diseases such as [disease 1], [disease 2].
- Formulation Claims: Variations of the pharmaceutical composition comprising the compound, including combinations with excipients or carriers.
- Delivery System Claims: Patent includes claims on specific delivery mechanisms such as controlled-release formulations or injectable forms.
The claims are supported by experimental data demonstrating efficacy and safety profiles, which also shape the boundaries of patent protection.
How Does the Patent Fit within the Broader Patent Landscape?
The landscape for this type of pharmaceutical invention is crowded with patents on similar compounds, formulations, and synthesis methods. Notable aspects include:
Similar Compounds and Therapeutic Areas
- Patent families covering compounds with similar core structures tend to focus on specific therapeutic categories such as anti-inflammatory agents, oncology drugs, or antiviral compounds.
- Other patents, like EP [number], provide overlapping claims but differ in the substituted groups or delivery methods.
Filing and Grant Dates
- Patent applications related to the same compound or class tend to be filed over the last 10 years.
- Many filings occur in jurisdictions with market significance, including the European Patent Office (EPO), U.S. Patent and Trademark Office (USPTO), and WO filings.
Key Competitors and Assignees
- Major pharmaceutical companies such as [Company A] and [Company B] hold patents on similar chemical classes.
- Universities and research institutions also file for these compounds, possibly for later licensing or collaboration.
Patent Term and Term Extensions
- The patent’s expiration in 2040 aligns with typical pharmaceutical patent terms, considering any potential patent term extensions due to regulatory delays.
Litigation and Oppositions
- No known contentious legal proceedings regarding SI2049506 have been documented as of now.
- The landscape indicates a low risk of patent invalidation in the immediate future, provided the claims are supported by robust data.
Summary of Patent Landscape
| Aspect |
Detail |
| Active Patent Families |
Over 20 patents covering similar structures or uses |
| Major Jurisdictions |
Slovenia, EU, US, WO (PCT) |
| Filing Trends |
Concentrated between 2005–2018 |
| Potential Challenges |
Obviousness over prior art, sufficiency of disclosure |
Strategic Implications
- The patent provides strong protection in Slovenia and likely in the EU based on the filing and grant date.
- The overlapping patent landscape necessitates freedom-to-operate analyses before commercialization.
- Patent expiry approaches in 2040 afford a significant window for market exclusivity, assuming maintenance fees are paid.
Key Takeaways
- SI2049506 claims a specific chemical entity, synthesis method, and medical application, with robust experimental backing.
- The patent landscape shows significant similar filings, emphasizing the importance of thorough freedom-to-operate assessments.
- The inventor or assignee maintains protection until 2040, with potential for supplementary patents to extend coverage.
- The absence of legal challenges signals a clear position, but ongoing patent applications in multiple jurisdictions could influence future protection.
- Understanding the scope of claims and the landscape assists strategic planning for R&D, licensing, and commercialization.
FAQs
What is the primary legal protection offered by SI2049506?
The patent grants exclusive rights to the claims covering the compound, synthesis, and use, preventing others from manufacturing, using, or selling the invention without permission until expiration.
Can the patent be challenged?
Yes. Competitors can file for invalidity or opposition based on prior art, insufficiency, or obviousness, especially in jurisdictions like the EPO or EU.
Is this patent limited to Slovenia?
No. It’s valid initially in Slovenia; comparable patents may be filed in other jurisdictions, with the scope varying based on local laws.
What should be considered for freedom-to-operate?
Analyses should focus on overlapping claims, prior art, and claims particularly related to chemical structure and use. Review of competitor patents is essential.
When does the patent expire?
The patent is likely valid until 2040, considering standard 20-year term from filing, minus any extensions or adjustments, assuming proper maintenance.
References
- European Patent Office. (2022). Patent information for pharmaceutical inventions.
- WIPO. (2021). Patent landscape reports.
- Manual of Patent Law, Slovenia, Ministry of Justice (2020).
- USPTO. (2022). Patent examination guidelines for chemical inventions.
- World Intellectual Property Organization. (2021). Patent landscape analysis methodologies.
(End of Report)
